Immupharma Regulatory News (IMM)

RNS REACH

IMMUPHARMA LAUNCHES NEW CORPORATE WEBSITE

PROVDING GREATER CLARITY ON LUPUZOR, CANCER AND ITS DEVELOPMENT PIPELINE

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug development company has today launched its new corporate website www.immupharma.com as part of its continued focus on improving how it communicates to investors, collaborators and potential licensing partners.

The new ImmuPharma website provides more detailed information about its two platform technologies and the Company's five lead compounds in development, each representing a potentially significant breakthrough in its field. This includes its lead product Lupuzor™, for the treatment of Lupus, which has recently received US FDA approval to enter Phase III with a Special Protocol Assessment and Fast Track designation and its cancer programme IPP-204106 which has a novel mechanism of action, aimed at preventing angiogenesis as well as proliferationand which was in May 2011 chosen to feature on the front cover of 'Cancer Research', the prestigious medical journal of the American Association for Cancer Research.

The website also provides more detail on ImmuPharma's key collaborator, Europe's largest fundamental research institution, the Centre National de la Recherche Scientifique (National Center for Scientific Research) or CNRS.

The website also includes an email alert service, for which shareholders are encouraged to register.

Dimitri Dimitriou, ImmuPharma's Chief Executive Officer, commented:

"We are seeking to provide improved information in this new website, which includes more detailed content to give a comprehensive and accessible overview of ImmuPharma's investment strategy, key assets including our discovery pipeline and the collaborators we work with such as CNRS." 

For further information please contact:

Website designed by Fruit Design

www.fruit-design.co.uk

Notes to Editors

ImmuPharma is focusing on developing novel medicines with high sales potential in specialist markets with serious unmet need. ImmuPharma has five drug candidates in development, two platform technologies and approximately 70 patents. The Company's most advanced drug candidate, LupuzorTM a potential blockbuster drug for Lupus, a chronic autoimmune disease has recently received the approval from the US FDA to enter phase III with a Special Protocol Assessment and "Fast Track" designation. ImmuPharma was founded and is led by a commercially focused Board and management team with extensive experience. www.immupharma.com